• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

生物库和风险评估:适应风险治理的风险综合分类。

Biobanking and risk assessment: a comprehensive typology of risks for an adaptive risk governance.

机构信息

BBMRI-ERIC, Graz, Austria.

Department of Science and Technology Studies, University of Vienna, Vienna, Austria.

出版信息

Life Sci Soc Policy. 2021 Dec 13;17(1):10. doi: 10.1186/s40504-021-00117-7.

DOI:10.1186/s40504-021-00117-7
PMID:34903285
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8666836/
Abstract

Biobanks act as the custodians for the access to and  responsible use of human biological samples and related data that have been generously donated by individuals to serve the public interest and scientific advances in the health research realm. Risk assessment has become a daily practice for biobanks and has been discussed from different perspectives. This paper aims to provide a literature review on risk assessment in order to put together a comprehensive typology of diverse risks biobanks could potentially face. Methodologically set as a typology, the conceptual approach used in this paper is based on the interdisciplinary analysis of scientific literature, the relevant ethical and legal instruments and practices in biobanking to identify how risks are assessed, considered and mitigated. Through an interdisciplinary mapping exercise, we have produced a typology of potential risks in biobanking, taking into consideration the perspectives of different stakeholders, such as institutional actors and publics, including participants and representative organizations. With this approach, we have identified the following risk types: economic, infrastructural, institutional, research community risks and participant's risks. The paper concludes by highlighting the necessity of an adaptive risk governance as an integral part of good governance in biobanking. In this regard, it contributes to sustainability in biobanking by assisting in the design of relevant risk management practices, where they are not already in place or require an update. The typology is intended to be useful from the early stages of establishing such a complex and multileveled biomedical infrastructure as well as to provide a catalogue of risks for improving the risk management practices already in place.

摘要

生物库是人类生物样本和相关数据的保管者,这些样本和数据是由个人慷慨捐赠的,旨在为公共利益和健康研究领域的科学进步服务。风险评估已成为生物库的日常实践,并从不同角度进行了讨论。本文旨在对风险评估进行文献回顾,以便将生物库可能面临的各种风险进行综合分类。本文采用的方法是类型学,其概念方法基于对生物库中科学文献、相关伦理和法律工具以及实践的跨学科分析,以确定如何评估、考虑和减轻风险。通过跨学科的映射练习,我们根据不同利益相关者的观点,如机构参与者和公众,包括参与者和代表性组织,制定了生物库中潜在风险的类型学。通过这种方法,我们确定了以下风险类型:经济风险、基础设施风险、制度风险、研究共同体风险和参与者风险。本文最后强调了适应性风险治理作为生物库良好治理的一个组成部分的必要性。在这方面,它通过协助设计相关的风险管理实践,为生物库的可持续性做出了贡献,而这些实践在生物库中尚不存在或需要更新。该类型学旨在从建立这种复杂的多层次生物医学基础设施的早期阶段就发挥作用,并为改进现有的风险管理实践提供风险目录。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7da0/8667387/387d9f3412b6/40504_2021_117_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7da0/8667387/8f05f7f878a7/40504_2021_117_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7da0/8667387/387d9f3412b6/40504_2021_117_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7da0/8667387/8f05f7f878a7/40504_2021_117_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7da0/8667387/387d9f3412b6/40504_2021_117_Fig2_HTML.jpg

相似文献

1
Biobanking and risk assessment: a comprehensive typology of risks for an adaptive risk governance.生物库和风险评估:适应风险治理的风险综合分类。
Life Sci Soc Policy. 2021 Dec 13;17(1):10. doi: 10.1186/s40504-021-00117-7.
2
Risk mapping for better governance in biobanking: the case of biobank.cy.生物样本库更好治理的风险映射:以biobank.cy为例
Front Genet. 2024 Jun 14;15:1397156. doi: 10.3389/fgene.2024.1397156. eCollection 2024.
3
Anticipatory Governance in Biobanking: Security and Risk Management in Digital Health.生物样本库的预期治理:数字健康中的安全和风险管理。
Sci Eng Ethics. 2021 Apr 21;27(3):30. doi: 10.1007/s11948-021-00305-w.
4
"It's all about trust": reflections of researchers on the complexity and controversy surrounding biobanking in South Africa.“一切都关乎信任”:研究人员对南非生物样本库相关复杂性与争议的反思
BMC Med Ethics. 2016 Oct 10;17(1):57. doi: 10.1186/s12910-016-0140-2.
5
Biobank networking and globalisation: perspectives and practices of Australian biobanks.生物银行网络与全球化:澳大利亚生物银行的视角与实践。
Aust Health Rev. 2021 Mar;45(2):214-222. doi: 10.1071/AH20063.
6
Determining the state of guidance on pediatric biobanking for researchers, HRECS, and families: Regulatory mapping of international guidance.确定针对研究人员、人类研究伦理委员会及家庭的儿科生物样本库指导方针状况:国际指导方针的监管映射
Eur J Pediatr. 2024 May;183(5):2477-2490. doi: 10.1007/s00431-024-05469-8. Epub 2024 Mar 13.
7
Biobanking in health care: evolution and future directions.生物银行在医疗保健中的应用:发展与未来方向。
J Transl Med. 2019 May 22;17(1):172. doi: 10.1186/s12967-019-1922-3.
8
Review of Indicators in the Context of Biobanking.生物库背景下的指标综述
Biopreserv Biobank. 2023 Aug;21(4):318-326. doi: 10.1089/bio.2022.0073. Epub 2022 Sep 13.
9
Ethical challenges in biobanking: moving the agenda forward in India.生物样本库中的伦理挑战:推动印度的议程向前发展。
Indian J Med Ethics. 2014 Apr 1;11(2):79-88. doi: 10.20529/IJME.2014.022.
10
The EuPA Biobank Initiative: Meeting the future challenges of biobanking in proteomics & systems medicine.欧洲蛋白质组学协会生物样本库倡议:应对蛋白质组学与系统医学中生物样本库的未来挑战
J Proteomics. 2015 Sep 8;127(Pt B):414-6. doi: 10.1016/j.jprot.2015.07.014.

引用本文的文献

1
Scalable summary-statistics-based heritability estimation method with individual genotype level accuracy.基于可扩展的摘要统计的遗传力估计方法,具有个体基因型水平的准确性。
Genome Res. 2024 Oct 11;34(9):1286-1293. doi: 10.1101/gr.279207.124.
2
Risk mapping for better governance in biobanking: the case of biobank.cy.生物样本库更好治理的风险映射:以biobank.cy为例
Front Genet. 2024 Jun 14;15:1397156. doi: 10.3389/fgene.2024.1397156. eCollection 2024.
3
Unlocking the potential of big data and AI in medicine: insights from biobanking.

本文引用的文献

1
Researchers' views on, and experiences with, the requirement to obtain informed consent in research involving human participants: a qualitative study.研究人员对涉及人类受试者的研究中获取知情同意要求的看法及经历:一项定性研究
BMC Med Ethics. 2020 Oct 2;21(1):93. doi: 10.1186/s12910-020-00538-7.
2
Global Public Perceptions of Genomic Data Sharing: What Shapes the Willingness to Donate DNA and Health Data?全球公众对基因组数据共享的看法:是什么影响了人们捐赠 DNA 和健康数据的意愿?
Am J Hum Genet. 2020 Oct 1;107(4):743-752. doi: 10.1016/j.ajhg.2020.08.023. Epub 2020 Sep 17.
3
Demographic and prosocial intrapersonal characteristics of biobank participants and refusers: the findings of a survey in the Netherlands.
挖掘大数据与人工智能在医学中的潜力:生物样本库的见解
Front Med (Lausanne). 2024 Jan 31;11:1336588. doi: 10.3389/fmed.2024.1336588. eCollection 2024.
4
Ethical layering in AI-driven polygenic risk scores-New complexities, new challenges.人工智能驱动的多基因风险评分中的伦理分层——新的复杂性,新的挑战。
Front Genet. 2023 Jan 26;14:1098439. doi: 10.3389/fgene.2023.1098439. eCollection 2023.
5
Paediatric biobanking for health: The ethical, legal, and societal landscape.儿科生物库与健康:伦理、法律和社会全景。
Front Public Health. 2022 Sep 27;10:917615. doi: 10.3389/fpubh.2022.917615. eCollection 2022.
6
Identification and Assessment of Risks in Biobanking: The Case of the Cancer Institute of Bari.生物样本库风险的识别与评估:以巴里癌症研究所为例。
Cancers (Basel). 2022 Jul 16;14(14):3460. doi: 10.3390/cancers14143460.
生物银行参与者和拒绝者的人口统计学和亲社会内在特征:荷兰调查的结果。
Eur J Hum Genet. 2021 Jan;29(1):11-19. doi: 10.1038/s41431-020-0701-1. Epub 2020 Jul 31.
4
«If you give them your little finger, they'll tear off your entire arm»: losing trust in biobank research.“如果你给他们小拇指,他们就会扯掉你的整条胳膊”:对生物银行研究失去信任。
Med Health Care Philos. 2020 Dec;23(4):565-576. doi: 10.1007/s11019-020-09969-w.
5
Consent and Privacy in the Era of Precision Medicine and Biobanking Genomic Data.精准医学和生物库基因组数据时代的同意与隐私。
Am J Law Med. 2020 May;46(2-3):167-187. doi: 10.1177/0098858820933493.
6
Treatment effects may remain the same even when trial participants differed from the target population.即使试验参与者与目标人群不同,治疗效果也可能保持不变。
J Clin Epidemiol. 2020 Aug;124:126-138. doi: 10.1016/j.jclinepi.2020.05.001. Epub 2020 May 11.
7
Future-proofing biobanks' governance.为生物银行的治理做好前瞻性规划。
Eur J Hum Genet. 2020 Aug;28(8):989-996. doi: 10.1038/s41431-020-0646-4. Epub 2020 May 18.
8
Possible consequences of the COVID-19 pandemic on the use of biospecimens from cancer biobanks for research in academia and bioindustry.新冠疫情对癌症生物样本库的生物样本用于学术研究和生物产业研究可能产生的后果。
Nat Med. 2020 Jun;26(6):809-810. doi: 10.1038/s41591-020-0890-8.
9
Genome studies must account for history-Response.
Science. 2019 Dec 20;366(6472):1461-1462. doi: 10.1126/science.aaz8941.
10
Genome studies reveal flaws in broad consent.基因组研究揭示了广泛同意存在的缺陷。
Science. 2019 Dec 20;366(6472):1460-1461. doi: 10.1126/science.aaz3797.